27 reports

  • COMPETITIVE LANDSCAPE
  • COMPETITIVE LANDSCAPE

TABLE OF CONTENTS ##.

  • Therapy
  • Market Competition
  • AstraZeneca PLC
  • CSL Limited
  • GlaxoSmithKline plc
  • OVERVIEW OF RECENT KEY EVENTS IN NASH
  • KEY GLOBAL METRICS (2026)

Therapy Directors Christopher J.

  • HIV Antiviral
  • Therapy
  • United States
  • World
  • Market Competition

Symptoms generally last for one to two weeks and are normally self-limiting without medical treatment.

  • Therapy
  • United States
  • Market Competition
  • Roche Group
  • Sanofi S.A.
  • ANOTHER ANTI-CD20 MAB GIVES MORE OPTIONS FOR THE TREATMENT OF MS

Novartis MS therapy Gilenya granted FDA Breakthrough Therapy designation for pediatric MS [##].

  • Therapy
  • United States
  • Market Competition
  • Novartis AG
  • TG Therapeutics, Inc.

SPHINGOSINE ##-PHOSPHATE RECEPTORS (S##PR## AND S##PR##) ARE THE OTHER TWO IMPORTANT TARGETS BEING FOCUSED ON BY DRUG DEVELOPERS FOR MS TREATMENT.

  • Therapy
  • United States
  • Market Competition
  • Biogen Idec Inc.
  • Novartis AG
  • COMPETITIVE LANDSCAPE
  • COMPETITIVE LANDSCAPE

It is one-time, lifesaving treatment and the most expensive treatment at approximately USD ##. ## million per patient.

  • Therapy
  • United States
  • Market Competition
  • Amgen Inc.
  • Biogen Idec Inc.

There are seven PGF targeting drugs, six of which are fusion proteins and one is RNAi gene therapy.

  • Therapy
  • Market Competition
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Roche Group
  • THE MAIN CLASSES OF DRUG ARE ANTITHROMBOTIC THERAPIES, LIPID-LOWERING AGENTS, AND ANTIHYPERTENSIVE AGENTS.
  • Clinical Event (clinical trial milestones)

CLINICAL TRIALS - ENROLLMENT ANALYTICS (PHASES I-III) ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Average No. of Subjects Enrolled Average Enrollment Efficiency (%) Source: GlobalData, Pharma Intelligence Center [Accessed June ##, 2018] © GlobalD

  • Therapy
  • Market Competition
  • AstraZeneca PLC
  • Esperion Therapeutics, Inc.
  • Janssen Biotech, Inc.

PIPELINE PRODUCTS - REGIONAL BREAKDOWN Stage United States Europe Japan Australia Global Pre-registration - ## ## - - Filing Rejected/ Withdrawn - ## - - - Phase III ## ## ## - ## Phase II ## ## - - ## Phase I ## ## ## ## ## Phase ## - - - - - IND/ CTA Filed -

  • Therapy
  • Market Competition
  • Incyte Corporation
  • Kiadis Pharma N.V.
  • Novartis AG

CHINA AND THE US ARE LEADING IN COUNTRY-SPECIFIC DRUG DEVELOPMENT. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Pre-registration ## ## Filing rejected/ Withdrawn Phase III ## ## ## ## Phase II ## ## ## Phase I ## ## ## ## Phase ## IND/ CTA Filed

  • Drug Development
  • Therapy
  • Market Competition
  • AbbVie Inc.
  • Gilead Sciences, Inc.

THESE POTENTIAL TARGETS COULD ALLOW A WIDER CHOICE FOR THOSE NONRESPONDING TO NSAIDS OR TNF INHIBITORS ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## NumberofDrugs Source: GlobalData, Pharma Intelligence Center [Accessed May 2018] PIPELINE PRODUCTS - REVIEW DESIG

  • Therapy
  • Market Competition
  • AbbVie Inc.
  • Eli Lilly & Co.
  • Novartis AG

GLOBALDATA RESEARCH CENTER ANALYST(S) ABOUT THE AUTHORS THERAPY AREA DIRECTOR Valentina Gburcik, PhD, is a Therapy Director for Cardiovascular and Metabolic Disorders.

  • Therapy
  • United States
  • Market Competition
  • Eisai Co., Ltd.
  • Novo Nordisk Group

Database Analysts ABOUT THE AUTHORS Therapy Area Director Christopher J.

  • Therapy
  • Market Competition
  • Allergan plc
  • Melinta Therapeutics, Inc.
  • Pfizer Inc.

Database Analysts ABOUT THE AUTHORS Therapy Area Director Valentina Gburcik, PhD, is a Therapy Director for Cardiovascular and Metabolic Disorders.

  • Therapy
  • United States
  • Market Competition
  • Eli Lilly & Co.
  • Novo Nordisk Group

IT IS ONE OF THE LEADING CAUSES OF BLINDNESS IN ADULTS.

  • Medical Biotechnology
  • Therapy
  • United States
  • Market Competition
  • Novartis AG
  • Brand (Generic Name)

Only one drug candidate in the pipeline is in Pre-Registration phase.

  • Therapy
  • China
  • United States
  • Market Competition
  • Eli Lilly & Co.

TMB-## (IBALIZUMAB) AND PRO-## ARE THE FIRST MABS TO DEMONSTRATE EFFICACY AS SALVAGE THERAPY OPTIONS AND AS MAINTENANCE THERAPY.

  • Therapy
  • United States
  • Market Competition
  • Gilead Sciences, Inc.
  • ViiV Healthcare Ltd.

• Do the KOLs believe there any barriers to using Avastin as a front-line treatment?

  • Ovarian Cancer
  • Targeted Therapy
  • Therapy
  • United States
  • Market Competition

Futura Medical Plc (UK) ##.

  • Condom
  • OTC
  • Therapy
  • World
  • Market Competition

(Australia) ##.

  • Healthcare
  • Mental Health
  • Neurological Disorder
  • Therapy
  • Market Competition
  • FROM 2018 TO 2020, A LARGE NUMBER OF TRIAL READOUTS COULD CHANGE THE G/GEJAC COMPETITIVE LANDSCAPE.
  • FROM 2018 TO 2020, A LARGE NUMBER OF TRIAL READOUTS COULD CHANGE THE G/GEJAC COMPETITIVE LANDSCAPE.

PD-(L)## checkpoint modulators are also evaluated in earlier lines of therapies where they could become SOC treatments.

  • Clinical Trial
  • Therapy
  • United States
  • Market Competition
  • Merck & Co., Inc.

TABLE OF CONTENTS ##.

  • Therapy
  • United States
  • World
  • Market Competition
  • GE Healthcare Limited
  • MONOCLONAL ANTIBODIES COMPETITIVE LANDSCAPE
  • OTHER MOLECULES

ASP-## Phase II VAP-## inhibitor Astellas Pharma ASP## is orally administered VAP-## inhibitor for treatment of diabetic nephropathy and diabetic macular oedema.

  • Therapy
  • Market Competition
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • COMPANY PROFILES AND COMPETITIVE LANDSCAPE
  • COMPANY PROFILES & COMPETITIVE LANDSCAPE

TABLE OF CONTENTS ##.

  • Pharmaceutical
  • Therapy
  • United States
  • Market Competition
  • Alexion Pharmaceuticals, Inc.

Researchers claim that it is one of the first treatments that can actually shrink enlarged hearts and significantly improve a damaged heart' s lifesustaining function.

  • Therapy
  • Market Competition
  • Bioheart, Inc.
  • Celladon Corporation
  • GlaxoSmithKline plc

This is one of the primary hindrances for the growth of the exosomes market.

  • Therapy
  • Company
  • Forecast
  • Market Competition
  • Thermo Fisher Scientific, Inc.

Global Injectable Drug Market (2017-2021 Edition) June 2017 ##.

  • Therapy
  • World
  • Market Competition
  • Market Size
  • Novartis AG